Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases
Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases
复制标题
DOI：
10.2165/00063030-200721010-00007
复制
发表时间：
2007-01-01
期刊：
影响因子：
6.8
通讯作者：
Figgitt, David P.
中科院分区：
文献类型：
--
作者：
Chapman, Therese M.;Plosker, Greg L.;Figgitt, David P.
VSL#3(VSL#3(R))是一种由8种活的冷冻干燥细菌组成的高浓度益生菌制剂，这些细菌是人类胃肠道微生物区系的正常组成部分，包括4株乳杆菌(干酪乳杆菌、植物乳杆菌、L嗜酸杆菌和德氏乳杆菌亚种)。Bulgaricus)、三株双歧杆菌(双歧杆菌长双歧杆菌、短双歧杆菌和婴儿双歧杆菌)和唾液链球菌亚种。来自非对比试验的数据表明，VSL#3在治疗活动期轻至中度溃疡性结肠炎以及作为缓解期溃疡性结肠炎患者的维持治疗方面具有临床潜力。此外，一项随机、开放的多中心试验表明，VSL#3与小剂量巴柳氮(美沙拉秦[美沙拉明；5-氨基水杨酸]的前体药物)联合治疗急性轻中度溃疡性结肠炎比标准剂量的巴沙拉齐或美沙拉秦单药更有效。随机、双盲、安慰剂对照研究表明，VSL#3在预防新形成的手术袋患者的急性膀胱炎发作以及在有难治性或复发性膀胱炎病史的患者接受抗菌治疗后维持缓解方面有效。美国和英国的治疗指南包括将VSL#3作为预防慢性膀胱炎患者复发的治疗选择。总体而言，VSL#3在临床试验中耐受性良好。设计良好的大型对照验证性临床试验将进一步确定VSL#3在治疗溃疡性结肠炎中的地位。
VSL#3 (VSL#3 (R)) is a high-concentration probiotic preparation of eight live freeze-dried bacterial species that are normal components of the human gastrointestinal microflora, including four strains of lactobacilli (Lactobacillus casei, L. plantarum, L acidophilus, and L. delbrueckii subsp. bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. breve, and B. infantis), and Streptococcus salivarius subsp. thermophilus.Data from noncomparative trials suggest that VSL#3 has clinical potential in the treatment of active mild to moderate ulcerative colitis and as maintenance therapy for patients with ulcerative colitis in remission. In addition, a randomized, open-label, multicenter trial showed that VSL#3 in combination with low-dose balsalazide (a prodrug of mesalazine [mesalamine; 5-aminosalicylic acid]) was more effective than standard doses of basalazide or mesalazine monotherapy in the treatment of acute mild to moderate ulcerative colitis. Randomized, double-blind, placebo-controlled studies have shown VSL#3 is effective in preventing the onset of acute pouchitis in patients with newly formed surgical pouches, and in maintaining remission following antibacterial treatment of acute pouchitis in patients with a history of refractory or recurrent pouchitis. Treatment guidelines from the US and the UK include VSL#3 as a therapeutic option for the prevention of pouchitis relapse in patients with chronic pouchitis. In general, VSL#3 was well tolerated in clinical trials. Large, well designed, controlled confirmatory clinical trials will further determine the place of VSL#3 in the treatment of ulcerative colitis.